Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
eNrFmNFu2jAUhu95iij3iQkUAlOg2li7IbUao0WbdoOc5FCcpXZqO0D39HMI3dIpWVtTq3cQO+cc278//3FwurtNrQ1wQRgd2Z7bti2gEYsJvRnZi+tzZ2CfjltBgje40k31czsd24pSLMTILlrdEDAV7vfLi4+g3gduj1tWwMIEIvmoXy5J6n7GYn2Js6KPFWwYia1bkGsWj+wsl/unViAkV1WMt4z/FBmOIECHJ9XWZHlSfR6gItgzouYC+AWmN7VBV1wrZpRzDlROsIQbxu9rQ2c89pad4aDvDQdaSYiYg2A5j2CG5XrG2YbEENcPA6cCtJKstvEV8E0KskhSGxwl0a3QCo4TvJvD3bS+6PeqdSJ30mk7nu/1e36v63dOej2tVLwyVfXyUYNA2bLb9vv+0EcrjmKISKFyh3ba3tBpe90+iiOUCJSSEK0xjVMIMReVn24iNJdyxrjEqaFFJGLyWJCG8nC4e1IsMRFZiu/VTGW6U4U5Vs3AFTbMDaQYwTVXIEvVnP0Tn+Zpil5Y9eKAGUMVFxSbsJzKBtqcz3UnYsKohF3ziuoBUu4OWiQgXi/sL0brD4dZHqYk0iWgYlQOQi7m02YAviE7PmABC24OHt8IjdlWvD6UqiIwVH2252p90GjZGfi9oa/vG34ovTWcXmc5ZxkgBSsijmHQlK7YsfRREq4P9SDgt9Lu3nuxCKfQ4L4cTW4p0T6YRWPbwtyWKxtqg346u9ZV09cc+P3V/m9taBKP/uhAD+omTgql3cbCX74TShz815eXWDgZdPVcec7rabOWMhPvkNo0whFYTZSrttobHxyVo93c54MR/1D6qRK/hkoPy1P1+Yupuy+fchfHOubD+wdnXptD8hyOWIcS4cZAOz17fXb/tcvGyp49Yo25NHtri6WChikPlYf1NxhHnRZqXek5V3D4slqRhjudRl0GqLxPGrcCVNwljVu/AQpRJG8=
NhEdUMTruW5eGDRr